Live Breaking News & Updates on பங்குகள் ஆராய்ச்சி

Stay informed with the latest breaking news from பங்குகள் ஆராய்ச்சி on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in பங்குகள் ஆராய்ச்சி and stay connected to the pulse of your community

Turning to renewable energy and healthcare

Ipmuda expected to return to the black in FY 2022

Kuala-lumpur , Malaysia , Tenom , Sabah , Kedah , Kelantan , Pokok-sena , Petaling-jaya , Baevinraj-thiagarajah , Jeefri-muhamad-yusup , Datuk-amiruddin-abdul-satar , Abu-sahid-mohamed

Duopharma slumps to 13-month low ahead of EGM

KUALA LUMPUR: Shares of Duopharma Biotech Bhd hit a near 13-month low of RM2.35 on Thursday ahead of its shareholders’ meeting the next day for the proposed bonus issue

Kuala-lumpur , Malaysia , Malaysian , Malaysians , Pharmaniaga-bhd , Sinovac-covid , Equities-research , Malaysia-vaccination-programme , Malaysia-drug-control-authority , Ta-research , China-national-biotec-group-co-ltd , Duopharma-biotech

CGS-CIMB Research retains Add for Duopharma, TP RM3.67

KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma
Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst.
It said on Monday it was keeping its forecasts intact for now pending the details or further developments in the supply agreement for the Sinopharm vaccine, which it thinks could be signed by end of the month.
“We retain our Add call on the stock with an unchanged TP of RM3.67 based on a CY22F P/E of 28.8 times (+2 standard deviations from its five-year mean),” the research house said.

Kuala-lumpur , Malaysia , Malaysian , Khairy-jamaluddin , Equities-research , Gamaleya-institute-of-russia , Malaysia-drug-control-authority , China-national-biotec-group-co-ltd , Immunisation-programme , World-health-organisation , Pfizer , Astrazeneca

BlackBerry Limited (BB) Q1 2022 Earnings Call Transcript

BlackBerry Limited (BB) Q1 2022 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

Australia , United-states , India , Netherlands , United-kingdom , China , Canada , France , America , Australian , Canadian , Paul-treiber

Guardians of NZ Superannuation appoints Charles Hyde

Guardians of NZ Superannuation appoints Charles Hyde
nbr.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbr.co.nz Daily Mail and Mail on Sunday newspapers.

Berkeley , California , United-states , Melbourne , Victoria , Australia , Sydney , New-south-wales , Charles-hyde , Stephen-gilmore , Nz-super-fund , University-of-california

CGS-CIMB Research keeps GDP forecast of 4.4% for 2021

KUALA LUMPUR: CGS-CIMB Equities Research is keeping its GDP forecast of 4.4% for 2021F, which incorporates the three phases of lockdown.

Kuala-lumpur , Malaysia , Malaysian , Inari-amertron-bhd , Pertuan-agong , National-recovery-plan , Equities-research , Telekom-malaysia , Public-bank , Public-bank-bhd , National-recovery , Analyst-reports

MPI to maintain double-digit US$ sales growth

Bhd (MPI) is expected to maintain double-digit US$ sales growth in the financial year ending June 2022 (FY6/22F), driven by robust demand for power management chips for electric vehicles (EVs) and data centres, a research house says.
CGS-CIMB Equities Research said MPI’s nine-month period ended March 31,2021 (9MFY6/21) core net profit beat expectations, at 84%/80% of its/Bloomberg consensus’ forecasts, due to stronger-than-expected sales in 3QFY21.
Its revenue grew 8.8% quarter-on-quarter (qoq) to RM527mil in 3QFY6/21 due to stronger contributions from all key markets — Asia (+7%), USA (+9.8%) and Europe (+13.3%). In US$ terms, MPI’s revenue rose 10% qoq in 3QFY21.
CGS-CIMB Research estimated Carsem’s plant in Ipoh and Suzhou were running at full capacity in the quarter.

Ipoh , Perak , Malaysia , Kuala-lumpur , United-states , Suzhou , Jiangsu , China , Malaysian , Bloomberg , Equities-research

AirAsia Group retains target to raise up to RM2.5b

AirAsia Group Bhd (AAGB) is retaining its target to raise RM2bil to RM2.5bil in new equity and debt capital this year, CGS-CIMB Equities Research said.

Kuala-lumpur , Malaysia , Malaysia-airlines , Airasia-group-bhd , Equities-research , Leasing-ltd , Airasia-group , Indonesia-airasia , Philippines-airasia , Analyst-reports , Aviation

IJM Corp 9M results above forecast, higher TP of RM2.03

IJM Corporation Bhd's nine-month results were above expectations as core net profit grew by 1.2% on-year but the overall group saw mixed performances except the plantations sector, CGS-CIMB Equities Research said.

Kuala-lumpur , Malaysia , Singapore , Equities-research , Corporation-bhd , Movement-control-orders-mcos , Coast-rail-link , Private-finance-initiative , Movement-control-orders , Analyst-reports , Construction

Improving earnings outlook for Sime Darby

CGS-CIMB Equities Research sees is upbeat on Sime Darby’s outlook as it sees improving earnings outlook beyond FY21F, driven by resilient motors demand in China and a stronger mining equipment demand in Australia.

China , Australia , Kuala-lumpur , Malaysia , Australian , Sime-darby , Bmw , Equities-research , Analyst-reports , Cgs-cimb-research , Motors-demand